The study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well-tolerated. The trial was designed to examine the safety, tolerability and effect on blood pressure in patients of repeat oral doses of SLx-2101 once daily for up to 14 days.
Jim Mahoney, president and CEO of Surface Logix, said: “These data confirm the promise of efficacy seen in earlier clinical trials, and we plan to initiate a Phase IIb study of SLx-2101 in hypertension in the third quarter of 2008. We believe that with our demonstrated 24-hour coverage from once-daily dosing and excellent tolerability profile, we will be able to uniquely position SLx-2101 in several segments of the hypertension market.”